Systematic Review of Renal Infarction Clinical Presentation, Causes, and Outcomes Authors: Mariam Nour Eldine, Hala Kilan, Patrick Hallak, Karumathil Murali, Siba Kallab, Sola A Bahous, Hicham Cheikh Hassan Published: 2026 ABSTRACT AbstractIntroductionRenal infarction is rare with only retrospective cohort studies published. To better understand renal infarction, we conducted a systematic review and metaanalysis of proportions for i) incidence and prevalence, ii) patient characteristics and symptoms, iii) causes, and iv) outcomes.MethodsWeb of Science, PubMed, and Scopus databases were searched. Articles were screened and data extracted with pooled measures determined by random effects metaanalysis of proportions with 95% confidence interval (95% CI). Heterogeneity was examined through I2.ResultsWe screened 4010 abstracts and included 34 retrospective cohort studies with 12,727 cases of renal infarction. Pooled incidence was 0.3 per 10,000 patient-years (95% CI, 0.04–2.3; I2 = 99%) and prevalence 0.017% (95% CI, 0.004–0.038; I2 = 99%). Comorbidity burden was high, with hypertension the most prevalent (0.47; 95% CI, 0.43–0.51; I2= 74%). Antithrombotic therapy was used in almost a third of patients (0.32; 95% CI, 0.21–0.45; I2 = 88%). The most common symptom was flank or abdominal pain (0.64; 95% CI, 0.46–0.81; I2 = 89%). Causes of renal infarction included embolic (0.42; 95% CI, 0.35–0.50; I2 = 97%), hypercoagulable state (0.12; 95% CI, 0.08–0.18; I2 = 85%), renal artery damage (0.11; 95% CI, 0.06–0.16, I2 = 97%), trauma (0.03; 95% CI, 0.01–0.06; I2 = 87%) and other or idiopathic (0.31; 95% CI, 0.25–0.37; I2 = 98%). Outcomes following a renal infarction included acute dialysis (0.04; 95% CI, 0.02–0.07, I2 = 39%), inpatient mortality (0.05; 95% CI, 0.03–0.09; I2 = 69%), chronic kidney disease (CKD) (0.25; 95% CI, 0.16–0.34; I2 = 89%), and kidney failure (0.04; 95% CI, 0.02–0.08; I2 = 77%).ConclusionRenal infarction is rare and can present with unspecific symptoms. Antithrombotic use should not exclude renal infarction from the differential and 25% develop CKD. There is a need to better standardize the classification.Keywords: Chronic kidney disease, incidence, kidney failure, prevalence, renal infarction, systematic review Renal infarction is the abrupt occlusion of a renal artery or one of its branches, causing disruption in renal blood flow, and subsequent ischemia leading to infarction.1,2 It is a rare and frequently misdiagnosed vascular event that, depending on severity, may lead to irreversible kidney damage resulting in CKD, renovascular hypertension, or kidney failure.2, 3, 4 To date the incidence and prevalence of renal infarction has not been clearly defined. Studies have reported variable prevalence ranging from 0.004%5 to 0.015%;6 however, autopsy studies report a much higher prevalence of 1.4%,7 indicating the condition is commonly misdiagnosed in routine practice. The clinical presentation of renal infarction is also highly nonspecific, variable, and can be confused with other more common diseases. Such presentations include common complaints of abdominal pain and/or flank pain that may be associated with fever, nausea, and/or vomiting.8 Renal infarction can also present with atypical features, such as acute uncontrolled hypertension,8,9 which may further mask the diagnosis and delay management. Causes of renal infarction can be diverse. The most common reported causes are of cardioembolic origins, with atrial fibrillation the leading cause in 65%–70% of cardioembolic causes.10,11 Noncardiogenic causes include hypercoagulable state and renal artery injury due to dissection, trauma, or inflammatory conditions.8,10,12,13 Despite extensive diagnostic studies, renal infarction remains classified as unknown or idiopathic in as much as 18%–30% of the patient population.10,13 Most studies reporting on renal infarction are small, retrospective cohorts, and describe prevalence, characteristics of the cohorts, and presentations with very few studies reporting on outcomes of a renal infarction. To date there has been no attempt to collate the information in a systematic review with a comprehensive assessment of the characteristics of patients with renal infarction. Given the rarity of the condition, the diverse clinical presentation and causes along with the limited information on outcome, we set out to conduct a systematic review and metaproportional analysis to better characterize the renal infarction population focusing on i) incidence and prevalence, ii) baseline characteristics of patients, iii) causes of renal infraction, and 4) outcomes including need for acute kidney replacement therapy (KRT), inpatient mortality, developing CKD, or progressing to kidney failure requiring chronic KRT. Methods This systematic review and metaanalysis of proportions was conducted according to a prespecified protocol and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 guideline for conducting a metaanalysis14 [Supplementary Material]. Search Criteria, Data Sources, and Search strategy A literature review was conducted to identify full-text and peer-reviewed cohort studies examining patients with renal infarction. We searched 3 online databases—PUBMED, Web of Science, and SCOPUS from inception until February 20, 2025 using combination of keywords, Medical Subject Heading terms, and subject headings for renal infarct. The search strategy is supplied in the Supplementary Material. Studies were included if they discussed patient characteristics, presentation, causes, or outcomes. Studies were excluded if they were non-English, conference abstracts, pediatric population, or those which examined only a specific patient population, such as renal transplantation, post procedures, or patients with amyloidosis only. References were exported and managed through Endnote software (version 20.6). Study Selection and Eligibility Criteria After duplicates were removed, titles and abstracts from the initial search were screened independently by 5 authors (MNE, PH, KM, HK, and HCH) based on eligibility criteria followed by independent full-text review by the same authors. All discrepancies were resolved by consensus. Data Extraction and Study Verification For publications meeting the selection criteria, data were extracted independently by the same 5 authors using a standardized data extraction form, with discrepancies resolved through consensus. We extracted the following data: study characteristics (author, year of publication, journal, study type, country, number of centers involved, and date of the study), cohort description (inclusion and exclusion criteria, definition of renal infarction, and diagnostic criteria), baseline characteristics (age, sex, body mass index, smoking status, comorbidities, previous antithrombotic use), presentation (time to diagnosis, presenting symptoms, and clinical signs), imaging findings, and causes of renal infarction. We also examined outcomes when reported, including inpatient mortality, need for acute KRT, developing CKD, or progressing to chronic KRT. The causes of renal infarction and their categorization was highly heterogenous across the included studies and pooling the data on the basis of the original study classification was not feasible. We therefore standardized the data extraction of causes of renal infarction and adopted a measure to be equally applied to all the studies. This approach allowed for a more consistent interpretation of the data and facilitated a more reliable pooling of the underlying causes of renal infarction despite the variability among studies. Risk of bias assessment was conducted by the 5 authors independently with disagreements resolved through consensus. We used the Joanna Briggs Institute Critical Appraisal Tool for the retrospective cohort studies.15 Studies were assigned an overall quality score ranging from 0 to 9, with scores ≤ 5 categorized as low-quality studies, 6–7 moderate quality, and 8–9 high-quality studies. Statistical Analysis Incidence rates were calculated for each study as the number of events divided by the total person-years of follow-up. The pooled incidence rates with corresponding 95% CI were then estimated with inverse variance weighting (DerSimonian and Laird method).16,17 To stabilize the variance and normalize the distribution, a logarithmic transformation was applied to the rates with the results then back transformed and presented as rates per 10,000 person years. For continuous variables, such as age, we pooled the mean with 95% CI by extracting from each study the sample size, mean, and SD, with studies weighted using the inverse variance method. For pooled proportional analysis a metaanalysis of proportional analysis was conducted using the double arcsine transformation to stabilize the variance as suggested by Freeman and Tukey18 with random-effects model used to account for anticipated heterogeneity among studies. Heterogeneity between studies was assessed using I2 statistic with heterogeneity assigned as low, moderate, or high corresponding to values of 25%, 50%, and 75%, respectively. Statistical analysis was performed using R (version 4.5.2). Results Study Selection and Characteristics We screened 4010 abstracts with 60 full-text articles retrieved. The final analysis included 34 studies (Figure 1), published between 1999 and 2025 and all were retrospective cohort studies.1,2,4,6,8,9,11, 12, 13,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43 A total of 2 studies, Chang et al.11 and Huang et al.,33 included the same study population but reported different measures and outcomes, so only 1 was used for each analysis. Of the 34 studies, 17 (50%) were published from Asia, with South Korea alone accounting for 9 (26%) publications. Other countries included France, Taiwan, Spain, Japan, and Turkey. Notably there were no included studies from African or South American countries. Flowchart of study selection. General characteristics of the included studies are summarized in Supplementary Table S1. The total number of patients with a renal infarction included in the analysis was 12,727. The smallest study had 7 patients,26 whereas the largest was a South Korean population analysis that included 10,496 cases of renal infarction.29 Risk of bias was assessed using the Joanna Briggs Institute scale for observational epidemiological studies (Supplementary Table S2). We found 17 (50%) studies with a high risk of bias, 15 (44%) with a moderate risk of bias, and 2 (6%) studies with a low risk of bias. The highest risk of bias was in the sampling frame for the target population, ensuring sufficient coverage of the identified population and an adequate response rate (Figure 2). Risk of bias assessment scores. For each question, a yes response indicated a low risk of bias, a no response indicated a high risk of bias, and an uncertain response indicated some concerns. Incidence and Prevalence Incidence was only examined in 3 studies,28,29,39 showing a pooled incidence of renal infarction in the general population of 0.3 per 10,000 patient-years (95% CI, 0.04–2.3) (Figure 3a). Prevalence was examined in 6 studies12,21,27, 28, 29,39 with a pooled proportion of 0.017% (95% CI, 0.004% –038%) (Figure 3b). The lowest prevalence was 0.007%27 and the highest was 0.085%.28 Heterogeneity was high for both incidence (I2 = 99%; P < 0.001) and prevalence (I2 = 99%; P < 0.001). Forest plot of pooled (a) incidence and (b) prevalence of renal infarction in studied populations. The squares represent the point estimates, the lines the 95% CI, and the area of the proportion the study weight. The diamond and the width represent the pooled estimates of the incidence or prevalence and the 95% CI. Baseline Demographics Table 1 describes the pooled age, body mass index, and proportion of demographic characteristics of patients with a renal infarction. The mean age was 59 years (95% CI, 56–62; I2 = 95%) with a body mass index of 25 kg/m2 (95% CI, 24–26; I2= 85%). There was a male predominance with a pooled male proportion of 0.60 (95% CI, 0.58–0.63; I2 = 39%), whereas the reported prevalence of smokers (current or former) was 0.44 (95% CI, 0.35– 0.53; I2 = 92%). Table 1Baseline demographic characteristics of patients with renal infarction by pooling the estimates with 95% CI across the studiesPoint Estimate (95% CI)I2Age (yrs)59.2 (56.3–62.1)94.8%BMI (kg/m2)25.0 (23.8–26.2)84.6%Sex (Male)0.60 (0.58–0.63)39.8%Smoking0.44 (0.35–0.53)92.4%CKD0.15 (0.08–0.25)93.0%Hypertension0.47 (0.43–0.51)73.5%Diabetes0.16 (0.13–0.18)86.6%Dyslipidemia0.28 (0.20–0.36)91.0%CardiovascularAtrial fibrillation0.38 (0.31–0.45)95.9%Valvular heart disease0.13 (0.06–0.22)87.2%Coronary artery disease0.17 (0.13–0.22)79.8%Congestive heart disease0.13 (0.07–0.19)89.3%Cerebrovascular disease0.12 (0.11–0.14)16.5%Embolic events0.13 (0.07–0.21)91.6%Peripheral vascular disease0.11 (0.06–0.15)63.2%Cancer0.08 (0.05–0.11)79.2%Current antithrombotic therapy0.32 (0.21–0.45)87.6% Antiplatelet0.21 (0.16–0.27)68.8% Warfarin0.15 (0.10–0.21)87.2%BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease.Point estimate was reported as the prevalence, except for age and BMI, where the point estimate was reported as the mean.Congestive heart disease includes cardiomyopathy.Cerebrovascular disease includes transient ischemic attacks and strokes.Embolic events include deep vein thrombosis, pulmonary embolus, and other embolic events. Baseline demographic characteristics of patients with renal infarction by pooling the estimates with 95% CI across the studies BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease. Point estimate was reported as the prevalence, except for age and BMI, where the point estimate was reported as the mean. Congestive heart disease includes cardiomyopathy. Cerebrovascular disease includes transient ischemic attacks and strokes. Embolic events include deep vein thrombosis, pulmonary embolus, and other embolic events. Comorbidity burden was high (Table 1), with hypertension the most prevalent with a pooled prevalence of 0.47 (95% CI, 0.43–0.51; I2 = 74%). Diabetes, dyslipidemia, and CKD were less common with a pooled prevalence of 0.16, 0.28, and 0.16 respectively. Cardiovascular comorbidity was frequently reported, with the commonest being atrial fibrillation (0.38; 95% CI, 0.31–0.45; I2 = 96%). Almost a third of patients with renal infarction were on current antithrombotic therapy (0.32; 95% CI, 0.21–0.45; I2 = 88%), such as an antiplatelet agent or warfarin. The forest plots of the pooled prevalence for the demographics are shown in the Supplementary Figures S1–S17. Heterogeneity was high (> 75%) in most of the pooled analysis except for sex, hypertension, peripheral vascular disease, and antiplatelet use (moderate) and cerebrovascular disease (low). Presentation of Renal Infraction The most common presenting symptom was flank and abdominal pain with a pooled prevalence of 0.64 (95% CI, 0.46–0.81; I2 = 89%), followed by proteinuria in 0.48 (95% CI, 0.37–0.58, I2 = 95%) (Table 2). The pooled prevalence of hematuria was 0.44 (95% CI, 0.34–0.54, I2 = 88%), and this could present as microscopic or macroscopic hematuria. Acute kidney injury was present in almost a third of cases at presentation (0.30; 95% CI, 0.23–0.39, I2 = 86%). Other presenting symptoms included fever (0.21; 95% CI, 0.16–0.27, I2 = 79%), nausea and vomiting (0.25; 95% CI, 0.15–0.38, I2= 83%). Atypical symptoms were also reported including dyspnea,1,4,13,36 altered mental status,13,26 anorexia,2 and acute or malignant hypertension.2,8,9,43 The left kidney was more likely to be affected than the right kidney (0.45 vs. 0.37), with the pooled prevalence of both kidneys infarcted in 0.17 (95% CI, 0.15–0.21; I2 = 56%). In addition to the kidneys, other organs were involved in 0.18 (95% CI, 0.14–0.22; I2= 55%), with the spleen, the organ most commonly affected (0.12; 95% CI, 0.0–- 0.17; I2 = 48%). Other organs with vascular infarction included liver,1,11,13 heart,4,24,33,40 lower extremities,33,37,39,43 lungs,1,11,40 the mesenteric circulation,23,33,36,37,39,40 and the central nervous system.11,13,22,24,33,39,40 The forest plots for the pooled prevalence of the presentations are presented in Supplementary Figures S18–S25. Table 2Clinical presentation of patients with renal infarction by pooling the estimates with 95% CI across the studiesPrevalence (95% CI)I2Flank and abdominal pain0.64 (0.46–0.81)88.6%Flank pain0.54 (0.42–0.65)90.3%Abdominal pain0.57 (0.45–0.70)90.2%Fever0.21 (0.16–0.27)78.7%Nausea and vomiting0.25 (0.15–0.38)83.3% Nausea0.26 (0.16–0.37)91.8% Vomiting0.18 (0.12–0.25)75.8%Hematuria0.44 (0.34–0.54)88.2%Proteinuria0.48 (0.37–0.58)94.6%AKI0.30 (0.23–0.39)86.3%Location Right kidney0.37 (0.34–0.41)41.9% Left kidney0.45 (0.42–0.48)25.5% Bilateral0.17 (0.15–0.21)56.2%Extrarenal infarction0.18 (0.14–0.22)54.8% Splenic infarction0.12 (0.08–0.17)47.8%AKI, acute kidney injury; CI, confidence interval.For flank and abdominal pain, studies were included if the proportion of the combined flank and abdominal pain was reported. If the proportion was reported as separate for flank pain or abdominal pain, then they were reported as a subgroup. A similar approach was used for nausea and vomiting.Extrarenal infarction included splenic infarction, abdominal infarction, lungs, liver, central nervous system, cardiac, and extremities infarction. Clinical presentation of patients with renal infarction by pooling the estimates with 95% CI across the studies AKI, acute kidney injury; CI, confidence interval. For flank and abdominal pain, studies were included if the proportion of the combined flank and abdominal pain was reported. If the proportion was reported as separate for flank pain or abdominal pain, then they were reported as a subgroup. A similar approach was used for nausea and vomiting. Extrarenal infarction included splenic infarction, abdominal infarction, lungs, liver, central nervous system, cardiac, and extremities infarction. High serum lactate dehydrogenase levels were reported in almost 70% of the studies, with the mean value on presentation ranging from 437.4 IU/L30 to 1608.7 IU/L.40 Time to diagnosis from symptom onset was also very variable, ranging from a mean of 7 hours42 to 5.4 days.8 We were unable to pool the analysis of lactate dehydrogenase and time to presentation because of the heterogeneity and inconsistency in reporting values. Causes of Renal Infarction A breakdown of the causes of renal infarctions is presented in Table 3, Figure 4, and Supplementary Figures S26 and S27. The commonest cause of renal infarction was of embolic origin (0.42; 95% CI 0.35–0.50; I2 = 97%) with arrythmias the most common (0.35; 95% CI, 0.26–0.44; I2 = 96%). Hypercoagulable state accounted for a pooled prevalence of 0.12 (95% CI, 0.08–0.18; I2 = 85%), with cancer as a cause contributing to a pooled prevalence of only 0.02 (95%CI, 0.01–0.04; I2 = 89%). The pooled prevalence of thrombophilia causes was 0.09 (95% CI, 0.04–0.14; I2 = 95%). Causes of thrombophilia resulting in renal infarction included antiphospholipid syndrome,1,8,11,13,19, 20, 21,24,25,32, 33, 34,36,43 hyperhomocysteinemia,8,13,32,42 JAK2 mutation,19 MTHFR C677T mutation,34 Factor V Leiden mutation,34,42 PAI mutation,34 prothrombin G20210A mutation,20 antithrombin deficiency,42 protein C deficiency,36,40,42 paroxysmal nocturnal hematuria,13 polycythemia,25,39 spherocytosis,20 and nephrotic syndrome.8,13 Table 3Causes of renal infarction by pooling the estimates with 95% CI across the studiesPrevalence (95% CI)I2Embolic origin0.42 (0.35–0.50)99.2% Arrythmia0.35 (0.26–0.44)96.4% Valvular0.05 (0.00–0.13)94.2% Cardiac nonvalvular0.01 (0.00–0.04)88.3% Extracardiac/infectious0.05 (0.03–0.08)61.1%Hypercoagulable state0.12 (0.08–0.18)84.9% Cancer0.02 (0.01–0.04)89.7% Thrombophilia/other0.09 (0.04–0.14)95.1%Renal artery damage0.11 (0.06–0.16)96.6%Trauma0.03 (0.01–0.06)87.0%Idiopathic/other0.31 (0.25–0.37)97.7%CI, confidence interval.Embolic cause was subgrouped into arrythmia (including atrial fibrillation), valvular (including artificial heart valves, rheumatic heard disease but excluding infectious causes), cardiac nonvalvular (including ventricular thrombus, auricular thrombus, cardiomyopathy, patent foramen ovale), or extracardiac/infectious cause (including aortic causes or infective causes such as infective endocarditis or septic emboli).Hypercoagulable state was subgrouped into cancer and thrombophilia/other.Renal artery damage includes FMD, renal artery aneurysm, aortic/renal artery dissection, arteritis, vasculitis, Ehlers-Danlos syndrome, Alagille syndrome, Marfan syndrome, compression from extra-renal causes.Other includes iatrogenic causes such as following surgery or endovascular procedures, substance abuse, sepsis, and hemodynamic instability in the critically ill or shock. Causes of renal infarction by pooling the estimates with 95% CI across the studies CI, confidence interval. Embolic cause was subgrouped into arrythmia (including atrial fibrillation), valvular (including artificial heart valves, rheumatic heard disease but excluding infectious causes), cardiac nonvalvular (including ventricular thrombus, auricular thrombus, cardiomyopathy, patent foramen ovale), or extracardiac/infectious cause (including aortic causes or infective causes such as infective endocarditis or septic emboli). Hypercoagulable state was subgrouped into cancer and thrombophilia/other. Renal artery damage includes FMD, renal artery aneurysm, aortic/renal artery dissection, arteritis, vasculitis, Ehlers-Danlos syndrome, Alagille syndrome, Marfan syndrome, compression from extra-renal causes. Other includes iatrogenic causes such as following surgery or endovascular procedures, substance abuse, sepsis, and hemodynamic instability in the critically ill or shock. Forest plot of pooled prevalence of the causes of renal infarction grouped into embolic origin, hypercoagulable state, renal artery damage, trauma, and idiopathic/other. Outcomes of Renal Infarction The pooled prevalence of need for acute KRT after renal infarction was 0.04 (95% CI, 0.02–0.07; I2 = 39%) whereas in-patient mortality occurred in 0.05 (95% CI, 0.03–0.09; I2 = 70%). The prevalence of developing CKD was 0.25 (95% CI, 0.16–0.35, I2 = 89%) whereas progressing to chronic KRT developed in 0.04 (95% CI, 0.02–0.08, I2 = 77%) (Table 4, Supplementary Figures S28–S31). Table 4Outcomes following a renal infarction by pooling the estimates with 95% CI across the studiesPrevalence (95% CI)I2Acute kidney replacement therapy0.04 (0.02–0.07)38.5%Inpatient mortality0.05 (0.03–0.09)69.7%CKD0.25 (0.16–0.34)89.1%Chronic kidney replacement therapy0.04 (0.02–0.08)76.8%CI, confidence interval; CKD, chronic kidney disease. Outcomes following a renal infarction by pooling the estimates with 95% CI across the studies CI, confidence interval; CKD, chronic kidney disease. Discussion We conducted a comprehensive systematic review and analysis of cohort studies examining renal infarction. To our knowledge this is the first study to extensively examine baseline characteristics, clinical presentation, causes, and outcomes of renal infarction where we included 12,727 patients, examining renal infarction across a wide range of geographic regions and settings. We confirmed that renal infarction is rare, with a prevalence of 0.017% and an incidence of 0.3 per 10,000 patient-years. However, only 3 and 6 studies examined the incidence the prevalence, respectively, and there was a large heterogeneity in the reported studies. As anticipated, patients with renal infarction have a high baseline comorbidity burden, with a high prevalence of hypertension, dyslipidemia, and cardiovascular disease. Atrial fibrillation was one of the commonest comorbidities, present in 38% of patients, and its presence should increase the index of suspicion of renal infarction. It was notable that almost a third of patients (32%) were on antiplatelet agents or warfarin. This should alert clinicians that being on an antiplatelet or warfarin should not exclude the possibility of a renal infarction, if the suspicion is high, and also suggests the possibility of inadequate dosing or noncompliance. Most studies did not present information on nonvitamin K antagonists oral anticoagulants (NOACs) use. We would recommend future studies to document nonvitamin K antagonists oral anticoagulants use in patients with renal infarction to note if they are of better efficacy than the traditional antiplatelet medications and warfarin. The most common presentation of renal infarction is flank and/or abdominal pain, which is expected. Proteinuria was present in 48% whereas hematuria was present in fewer than half (44%). The presence of proteinuria and the absence of hematuria should therefore not reassure clinicians or be used to exclude the diagnosis. Clinical presentation for patients with renal infarction can also be highly variable, with some patients presenting with nausea and vomiting, fever, or dyspnea. Again, this reinforces that a high clinical suspicion would be needed to rule out a renal infarction. Finally, we did not find any inflammatory marker or response to assist in identifying or excluding a diagnosis of renal infarction. Only 1 study included in the analysis31 compared renal infarction with acute pyelonephritis and found that a lower, rather than a higher, C-reactive protein favored an infarction, with asparate aminotransferase being the marker that discriminated. Another study6 examined 2131 patients presenting with flank pain, 39 of whom had a renal infarction. They found no inflammatory marker among the independent predictors. None of the studies supported using an inflammatory response to aid in identifying or excluding the diagnosis of a renal infarction. Our metaanalysis of proportions showed a large heterogeneity in the included studies. The heterogeneity is anticipated given the rarity of the disorder, the retrospective nature of all included studies, and the variable clinical settings. Some studies diagnosed renal infarction through hospital coding, which are prone to errors. The rest of the studies relied on imaging, particularly computed tomography scans with contrast, which will require a high index of suspicion to be ordered. Studies also ranged from the small hospital cohorts (with 7 cases included) to large population studies (with > 10,000 cases included). Although the variability may seem a challenge, we believe that pooling all the available studies to provide a framework on renal infarction through a metaanalysis of proportions to be an effective strategy to better clarify the disease and report on its characteristics. The main analysis where heterogeneity was clear was in reporting causes. There currently exists no clear framework for reporting causes, and numerous studies grouped different etiologies under different groups. At the onset we went with classifying causes as cardiac, hypercoagulable state, renal artery damage, trauma, and idiopathic or other—which appeared to be the most consistent approach among the reported retrospective studies. We individually counted each cause in each study before deciding on the appropriate heading; for example, some studies labelled renal infarction following surgery as trauma related, whereas in our analysis we placed them under idiopathic or other as iatrogenic. Similarly in all our analysis we labelled vasculitis as a renal artery damage, whereas some studies may have classified them as hypercoagulable. By determining beforehand how each etiology should be grouped, and consistently adhering to our protocol, we ensured that our results are consistent. We would recommend that every study reports outcomes in a consistent pattern, and although our study may be used as a framework to report etiologies, we acknowledge that such frameworks are probably best determined by a working group. This would improve consistency in reporting, facilitate comparative research, and enhance the overall understanding of underlying etiologies of renal infarction. Most studies, and most discussions, on renal infarctions focus on the diagnosis, presentation, and causes. Our analysis was the first to examine outcomes systematically and methodologically. We showed that renal infarction can be associated with short term adverse events, such as need for acute KRT and inpatient mortality, and long-term adverse events, such as developing CKD or progressing to chronic KRT. The risk of CKD was high, with a pooled prevalence of 25% of patients developing CKD. Progressing to chronic KRT is also increased, with a pooled prevalence of 4%. We note that the number of studies addressing long-term outcomes are limited and would further recommend that outcomes be incorporated into further research to better understand prognosis, optimize management strategies, and improve patient outcomes. Management of renal infarction remains poorly standardized, as no randomized controlled trials exist with current recommendations largely based on retrospective studies and extrapolation from other ischemic conditions. Systemic anticoagulation is considered the mainstay of treatment, particularly in thromboembolic cases, and is commonly initiated with heparin followed by oral anticoagulant agents; available data suggest no clear advantage of more aggressive therapies over anticoagulation alone.8 In selected patients, especially those presenting early with significant arterial occlusion, catheter-directed thrombolysis or endovascular interventions may be considered with the aim of preserving renal function, although evidence is limited and outcomes vary depending on factors, such as ischemia duration and baseline kidney function.37 Supportive care, including blood pressure control, adequate hydration, and avoidance of nephrotoxic agents, remains essential. Treatment should also be tailored to the underlying etiology, with anticoagulation favored in embolic or hypercoagulable states and antiplatelet therapy in selected vascular causes. The optimal duration of therapy is guided by the cause of the renal infarction and inferred from how other infarctions are treated. In idiopathic causes, the duration of anticoagulation therapy remains unclear. Only 1 included study37 advised a duration policy, recommending a minimum of 3 months for identified causes of renal infarction and a minimum of 6 months in idiopathic causes. Another included study33 confirmed that anticoagulation is associated with a better survival and fewer thromboembolic complications but did not report duration. Finally, recurrence after idiopathic infarction appears low with 1 study showing no arterial recurrence in the idiopathic group.32 However, the same cohort also showed that 10% of patients initially classified as idiopathic were subsequently diagnosed with atrial fibrillation. Our recommendation, therefore, would be for anticoagulation to continue for a minimum of 3–6 months until etiologic evaluation is complete. If the cause of the renal infarction is still undetermined, then we recommend the need for an individualized approach, balancing the suspected underlying mechanism, recurrence risk, and bleeding risk with treatment decisions guided by clinical judgement. We also advise that this remains an area of priority for future prospective studies, in order to better inform patients and physicians on the optimal duration of treatment. A key strength of this study is the comprehensive search strategy allowing an in-depth review of renal infarction from multiple relevant perspectives starting with presentation, etiologies, features, and finally outcomes. Moreover, the inclusion of a large number of patients and the broad representation of participants across different subgroups and from different countries allowed for a greater generalizability of the results to a wider population. The study is also distinguished by its inclusive approach, where patients with diverse baseline characteristics were incorporated which might further support the external validity of the results. We acknowledge our limitations, primarily the high between-study heterogeneity which we have discussed. There are many causes for this including differences in study design, patient populations, diagnostic criteria, and the high risk of bias in some measures. However, we still believe our results hold importance and validity when it comes to assessing renal infarction populations. We should also acknowledge that all included studies are retrospective cohort studies, with all the biases such studies contained also inferred from our analysis. Most included studies were also single center. Although we believe our study is generalizable, we note that there is a deficiency of reported populations, such as from South America or Africa; however, we acknowledge this may be because of limiting our inclusion to English language only. Our study was also unable to pool laboratory parameters because of inconsistent reporting. This would have been useful in showing if some inflammatory markers or laboratory data (such as C-reactive protein, erythrocyte sedimentation rate, white cell count, and lactate dehydrogenase) may assist in increasing the suspicion of a renal infarct diagnosis for clinicians. Finally, small study effects may further distort the results, especially in rare conditions, such as what was examined in this analysis. In conclusion, renal infarction is rare and can present with a very wide clinical picture. A high index of suspicion is needed. We recommend that definitions and classifications of etiologies be standardized in order to improve comparability across studies, and hope our study allows for a framework. There is a need for a prospective multicenter study to better clarify this population, which should ideally be well-designed and multicentered. Finally, greater emphasis should be placed on evaluating long-term outcomes after diagnosis and management, including renal function, recurrence risk, and overall survival. Collectively, these efforts would provide more robust evidence to guide clinical decision-making, refine treatment strategies, and ultimately improve patient care. Disclosure All the authors have no competing interests to disclose. Footnotes Supplementary File (PDF) PRISMA Checklist. Search strategy in PUBMED, Wed of Science, and SCOPUS. Figure S1. Forest plot for mean age in patients with renal infarction. Figure S2. Forest plot for mean BMI in patients with renal infarction. Figure S3. Forest plot for prevalence of males in patients with renal infarction. Figure S4. Forest plot for prevalence of smokers in patients with renal infarction. Figure S5. Forest plot for prevalence of chronic kidney disease in patients with renal infarction. Figure S6. Forest plot for prevalence of hypertension in patients with renal infarction. Figure S7. Forest plot for prevalence of diabetes in patients with renal infarction. Figure S8. Forest plot for prevalence of dyslipidemia in patients with renal infarction. Figure S9. Forest plot for prevalence of atrial fibrillation in patients with renal infarction. Figure S10. Forest plot for prevalence of valvular heart disease in patients with renal infarction. Figure S11. Forest plot for prevalence of coronary artery disease in patients with renal infarction. Figure S12. Forest plot for prevalence of congestive heart disease in patients with renal infarction. Figure S13. Forest plot for prevalence of cerebrovascular disease in patients with renal infarction. Figure S14. Forest plot for prevalence of embolic events in patients with renal infarction. Figure S15. Forest plot for prevalence of peripheral vascular disease in patients with renal infarction. Figure S16. Forest plot for prevalence of cancer in patients with renal infarction. Figure S17. Forest plot for prevalence of anticoagulation uses in patients with renal infarction. Figure S18. Forest plot for prevalence of presentation with flank and abdominal pain in patients with renal infarction. Figure S19. Forest plot for prevalence of presentation with fever in patients with renal infarction. Figure S20. Forest plot for prevalence of presentation with nausea and vomiting in patients with renal infarction. Figure S21. Forest plot for prevalence of presentation with hematuria in patients with renal infarction. Figure S22. Forest plot for prevalence of presentation with proteinuria in patients with renal infarction. Figure S23. Forest plot for prevalence of presentation with acute kidney injury in patients with renal infarction. Figure S24. Forest plot for prevalence of location of renal infarction. Figure S25. Forest plot for prevalence of extra-renal infarction in patients with renal infarction. Figure S26. Forest plot for prevalence of embolic causes of renal infarctions. Figure S27. Forest plot for prevalence of hypercoagulable causes of renal infarctions. Figure S28. Forest plot for prevalence of patients needing acute kidney replacement therapy following a renal infarction. Figure S29. Forest plot for prevalence of patients with an in-patient mortality following a renal infarction. Figure S30. Forest plot for prevalence of patients who developed chronic kidney disease following a renal infarction. Figure S31. Forest plot for prevalence of patients who progressed to chronic kidney replacement therapy following a renal infarction. Table S1. General Characteristics of included studies. Table S2. Risk of bias assessment based on JBI Scale. Supplementary Material Supplementary File (PDF) PRISMA Checklist. Search strategy in PUBMED, Wed of Science, and SCOPUS. Figure S1. Forest plot for mean age in patients with renal infarction. Figure S2. Forest plot for mean BMI in patients with renal infarction.Figure S3. Forest plot for prevalence of males in patients with renal infarction. Figure S4. Forest plot for prevalence of smokers in patients with renal infarction. Figure S5. Forest plot for prevalence of chronic kidney disease in patients with renal infarction. Figure S6. Forest plot for prevalence of hypertension in patients with renal infarction. Figure S7. Forest plot for prevalence of diabetes in patients with renal infarction. Figure S8. Forest plot for prevalence of dyslipidemia in patients with renal infarction. Figure S9. Forest plot for prevalence of atrial fibrillation in patients with renal infarction. Figure S10. Forest plot for prevalence of valvular heart disease in patients with renal infarction. Figure S11. Forest plot for prevalence of coronary artery disease in patients with renal infarction. Figure S12. Forest plot for prevalence of congestive heart disease in patients with renal infarction. Figure S13. Forest plot for prevalence of cerebrovascular disease in patients with renal infarction. Figure S14. Forest plot for prevalence of embolic events in patients with renal infarction. Figure S15. Forest plot for prevalence of peripheral vascular disease in patients with renal infarction. Figure S16. Forest plot for prevalence of cancer in patients with renal infarction. Figure S17. Forest plot for prevalence of anticoagulation uses in patients with renal infarction. Figure S18. Forest plot for prevalence of presentation with flank and abdominal pain in patients with renal infarction. Figure S19. Forest plot for prevalence of presentation with fever in patients with renal infarction. Figure S20. Forest plot for prevalence of presentation with nausea and vomiting in patients with renal infarction. Figure S21. Forest plot for prevalence of presentation with hematuria in patients with renal infarction. Figure S22. Forest plot for prevalence of presentation with proteinuria in patients with renal infarction. Figure S23. Forest plot for prevalence of presentation with acute kidney injury in patients with renal infarction. Figure S24. Forest plot for prevalence of location of renal infarction. Figure S25. Forest plot for prevalence of extra-renal infarction in patients with renal infarction. Figure S26. Forest plot for prevalence of embolic causes of renal infarctions. Figure S27. Forest plot for prevalence of hypercoagulable causes of renal infarctions. Figure S28. Forest plot for prevalence of patients needing acute kidney replacement therapy following a renal infarction. Figure S29. Forest plot for prevalence of patients with an in-patient mortality following a renal infarction. Figure S30. Forest plot for prevalence of patients who developed chronic kidney disease following a renal infarction. Figure S31. Forest plot for prevalence of patients who progressed to chronic kidney replacement therapy following a renal infarction. Table S1. General Characteristics of included studies. Table S2. Risk of bias assessment based on JBI Scale. References Associated Data Supplementary Materials Supplementary File (PDF) PRISMA Checklist. Search strategy in PUBMED, Wed of Science, and SCOPUS. Figure S1. Forest plot for mean age in patients with renal infarction. Figure S2. Forest plot for mean BMI in patients with renal infarction.Figure S3. Forest plot for prevalence of males in patients with renal infarction. Figure S4. Forest plot for prevalence of smokers in patients with renal infarction. Figure S5. Forest plot for prevalence of chronic kidney disease in patients with renal infarction. Figure S6. Forest plot for prevalence of hypertension in patients with renal infarction. Figure S7. Forest plot for prevalence of diabetes in patients with renal infarction. Figure S8. Forest plot for prevalence of dyslipidemia in patients with renal infarction. Figure S9. Forest plot for prevalence of atrial fibrillation in patients with renal infarction. Figure S10. Forest plot for prevalence of valvular heart disease in patients with renal infarction. Figure S11. Forest plot for prevalence of coronary artery disease in patients with renal infarction. Figure S12. Forest plot for prevalence of congestive heart disease in patients with renal infarction. Figure S13. Forest plot for prevalence of cerebrovascular disease in patients with renal infarction. Figure S14. Forest plot for prevalence of embolic events in patients with renal infarction. Figure S15. Forest plot for prevalence of peripheral vascular disease in patients with renal infarction. Figure S16. Forest plot for prevalence of cancer in patients with renal infarction. Figure S17. Forest plot for prevalence of anticoagulation uses in patients with renal infarction. Figure S18. Forest plot for prevalence of presentation with flank and abdominal pain in patients with renal infarction. Figure S19. Forest plot for prevalence of presentation with fever in patients with renal infarction. Figure S20. Forest plot for prevalence of presentation with nausea and vomiting in patients with renal infarction. Figure S21. Forest plot for prevalence of presentation with hematuria in patients with renal infarction. Figure S22. Forest plot for prevalence of presentation with proteinuria in patients with renal infarction. Figure S23. Forest plot for prevalence of presentation with acute kidney injury in patients with renal infarction. Figure S24. Forest plot for prevalence of location of renal infarction. Figure S25. Forest plot for prevalence of extra-renal infarction in patients with renal infarction. Figure S26. Forest plot for prevalence of embolic causes of renal infarctions. Figure S27. Forest plot for prevalence of hypercoagulable causes of renal infarctions. Figure S28. Forest plot for prevalence of patients needing acute kidney replacement therapy following a renal infarction. Figure S29. Forest plot for prevalence of patients with an in-patient mortality following a renal infarction. Figure S30. Forest plot for prevalence of patients who developed chronic kidney disease following a renal infarction. Figure S31. Forest plot for prevalence of patients who progressed to chronic kidney replacement therapy following a renal infarction. Table S1. General Characteristics of included studies. Table S2. Risk of bias assessment based on JBI Scale.